Oral and intravenous products for correcting fluid and electrolyte imbalance will present no risk to a breastfeeding infant as they are normally present in milk.
Plasma and plasma substitutes will present no risk to a breastfed infant due to their molecular size and mechanism of action in expanding plasma volume.